BD Unveils New Automated Preparation Solution for Microbial Identification
BD Kiestra™ IdentifA system is available in Europe (CE marked) and Canada
Nov 18, 2019
FRANKLIN LAKES, NJ (November 18, 2019) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) and Canada for the BD Kiestra™ IdentifA system. The new solution helps bring accuracy and efficiency to preparing samples for microbial identification. By automating the sample processing steps required to identify a microorganism, this solution helps reduce potential for user error while providing clinicians with bacterial identification for a patient suspected of having an infection.
“Microbial identification is a critical laboratory operation that informs all downstream microbiology testing but often requires a significant amount of hands-on-time,” said Steve Conly, vice president of microbiology at BD. “Over the coming years, we look forward to continuing to build on our laboratory automation solutions and help laboratories answer microbiology questions with greater ease, eliminating errors that can result from inefficient and manual procedures.”
The BD Kiestra™ IdentifA solution, which is available as part of a track-based BD Kiestra™ laboratory automation solution, supports specimen preparation workflows for routine and challenging isolate types in combination with identification on the BD Bruker MALDI Biotyper®. Through integration with the BD Synapsys™ Microbiology Informatics solution, it may also accelerate communication of laboratory test results to clinicians to inform their decision-making.
BD continues to invest in automation and innovation for the microbiology laboratory, including for antibiotic susceptibility testing. For more information on BD Kiestra™ lab automation solutions, please visit https://www.bd.com/en-us/offerings/capabilities/lab-automation.
About the BD Kiestra™ lab automation solutions
BD Kiestra™ lab automation solutions provide total lab automation for the clinical microbiology lab through modularity, scalability and open architecture. These solutions are designed to increase efficiency, streamline processes, and deliver high quality and consistent results with improved turnaround time. BD Kiestra™ lab automation offerings include complementary and modular microbiology workflow automation solutions, ranging from standalone units to fully automated track-based automation systems for mid- and high-volume labs.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.
For more information on BD, please visit bd.com.
Monique N. Dolecki
201 847 5378
Back to News Releases